This clinical trial focuses on patients with advanced/metastatic cancers who have already received at least one prior treatment. The study tests several medications including Lynparza (olaparib), Tasigna (nilotinib), Imjudo (tremelimumab), and Imfinzi (durvalumab). These medications are given to patients whose tumors have specific molecular changes that suggest they might respond to these treatments.
The purpose of this study is to evaluate if continuing treatment after an initial period (called maintenance treatment) helps control cancer growth better than stopping treatment. The study is divided into two parts: an initial treatment period and a maintenance period. During the initial period, patients receive one of the study medications. Those who show stable disease or improvement may continue to the maintenance period.
The treatment plan involves taking medications either by mouth as tablets or through intravenous infusion (given directly into a vein). The medications are chosen based on specific features found in each patient’s tumor through molecular testing. The study monitors how well the treatment works and how long it can keep the cancer from growing, while also checking for any side effects that may occur during treatment.



France